Scale Up

Mar 02, 2008
BioPharm International
The future of therapeutic MAbs lies in the development of economically feasible downstream processes.
Mar 02, 2008
BioPharm International
An alternative approach to traditional Protein A schemes is comparable in overall efficiency, product recovery, and quality.
Mar 02, 2008
BioPharm International
Manufacturing challenges surround the use of IgM monoclonal antibodies, but these can be overcome with current technology.
Feb 01, 2008
BioPharm International
The use of disposables has changed significantly in the biopharmaceutical industry.
Jan 01, 2008
BioPharm International
By BioPharm International Editors
Design space concepts are key to a successful technology transfer.
Nov 02, 2007
BioPharm International
A solution for the problems of a "bag in a can" system would be a fully jacketed and insulated container, similar to a traditional freeze tank.
Oct 01, 2007
BioPharm International
By BioPharm International Editors
It became a strategic imperative to find a better, more efficient way to manufacture our products. To continue with the status quo was untenable.
Oct 01, 2007
BioPharm International
By BioPharm International Editors
It is commonly believed that technologies in the next 10–15 years will enable sequencing an individualized human genome for less than $1,000. With innovations like these, the twenty-first century will certainly belong to biotechnology. From an industrial standpoint, the discovery of therapeutic molecules and the development of cell lines and processes to produce these molecules will be of paramount importance. This article describes various approaches that have been prevalent in the industry or are likely to be used in the future for generating cell lines with desirable traits and developing high titer cell culture processes.
Oct 01, 2007
BioPharm International
Low-pressure process chromatography could not have developed without immense efforts to resolve scale-up issues in both column design and matrix stability.
Sep 13, 2007
BioPharm International
By BioPharm International Editors
Small biotechnology companies often need guidance during the development of new therapies—particularly when it comes to manufacturing.
native1_300x100
lorem ipsum